The original call
Original year: 2023
2026 assessment
Scorecard verdict: Tracking - too early to grade
Tracking — too early to grade, and I want to be upfront about that. The science is genuinely staggering: lab-grown tissue, bioprinted structures, stem-cell therapies, and the first gene-edited and engineered-cell breakthroughs are real and accelerating. But “growing human organs for transplant” as a routine clinical reality? Not yet. We’re in the lab and the early trials, not the operating room at scale. I stand behind the direction completely. I’m just not going to pretend the destination has arrived when it hasn’t. Ask me again in 2030 — this is the one I most want to re-grade.